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MitochondriaAgeing is associatedwith functional, structural andmechanical changes in arteries that closely resemble the vas-
cular alterations in hypertension. Characteristic features of large and small arteries that occur with ageing and
during the development of hypertension include endothelial dysfunction, vascular remodelling, inﬂammation,
calciﬁcation and increased stiffness. Arterial changes in young hypertensive patients mimic those in old normo-
tensive individuals. Hypertension accelerates and augments age-related vascular remodelling and dysfunction,
and ageingmay impact on the severity of vascular damage in hypertension, indicating close interactions between
biological ageing and blood pressure elevation. Molecular and cellular mechanisms underlying vascular alter-
ations in ageing and hypertension are common and include aberrant signal transduction, oxidative stress and ac-
tivation of pro-inﬂammatory and pro-ﬁbrotic transcription factors. Strategies to suppress age-associated vascular
changes could ameliorate vascular damage associatedwith hypertension. An overview on the vascular biology of
ageing and hypertension is presented and novel molecular mechanisms contributing to these processes are
discussed. The complex interaction between biological ageing and blood pressure elevation on the vasculature
is highlighted. This article is part of a Special Issue entitled: CV Ageing.
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Clinical studies show a signiﬁcant relationship between ageing and
increased blood pressure, with advancing age being a major non-
modiﬁable risk factor in the development of hypertension [1]. This is
due, in part, to changes that occur in the vasculature, including endothe-
lial dysfunction, vascular remodelling, increased vascular stiffness and
inﬂammation. These functional and structural changes deﬁne the
‘vascular phenotype’ of hypertension, features that are also found
during ageing [2] (Fig. 1). At the cellular level, there is endothelial cell
damage, increased vascular smooth muscle cell growth, cell migration,
inﬂammation, contraction, extracellular matrix deposition, ﬁbrosis,
and calciﬁcation [3].
Young patientswith elevated blood pressure exhibit arterial changes
similar to those in older individuals with normal blood pressure, and
accordingly the concept of ‘premature’ or ‘early’ vascular ageing in
hypertension has been proposed [4]. Hypertension accelerates age-
related vascular changes, processes that are attenuated when blood
pressure is normalised. The direct relationship between ageing and vas-
cular health is evident in progeria syndrome, where patients exhibit ac-
celerated ageing, endothelial dysfunction, accelerated atherosclerosis
and die prematurely from complications of cardiovascular disease,
such as stroke and myocardial infarction [5]. Considering the fact that
the population is ageing and that the major chronic disease of ageing
is hypertension and associated cardiovascular complications, the poten-
tial health and economic burden in ourmodern society is enormous. Ac-
cordingly it is important to understand how vascular function changes
with ageing and how this impacts on hypertension, so that targeted
strategies could be developed to prevent and repair damaged ‘aged’
arteries and thereby reduce the risk of hypertension and target organLumen(L)
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Media
(M)
Fig. 1. Schematic demonstrating vascular changes that occur during ageing and with the devel
observed with ageing.damage. In the present review, we discuss the vascular changes that
occur with ageing and during the development of hypertension and
focus on some molecular mechanisms that underlie these vascular
changes.
2. Structural and mechanical changes in the ageing vasculature
Physiological changes to the vascular wall are dynamic and occur
throughout life [6,7]. Endothelial cell turnover occurs over years,where-
as that of vascular smooth muscle cells seems to occur over a shorter
time period. Many structural and mechanical alterations have been ob-
served in the aged vasculature including increased intimal-to-media
(IM) thickness, evidenced by the ﬁnding that the IM thickness of the
carotid artery increases two- to three-fold between 20 and 90 years of
age [8,9]. Subclinical IM thickening is strongly associated with ageing
and is also a predictor of future cardiovascular events [8,9]. Both aortic
length and circumference gradually increase with advancing age
[10–12]. Associated with these structural alterations are mechanical
changes, characterised by a reduction in compliance, reduced elasticity/
distensibility and increased stiffness [8,9]. Stiffening of the large conduit
arteries due to fracture of elastin ﬁbres within the tunica media and
collagenous remodelling, results in increased aortic pulse pressure and
pulse wave velocity (PWV). Increased PWV, a non-invasive measure of
vascular stiffness, increases in both sexes with ageing and is determined
by the mean arterial pressure and the intrinsic stress/strain relationship
(stiffness) of the arterial wall. As arterial wall stiffness increases, central
systolic pressure increases and diastolic pressure decreases, leading to
increased pulse pressure, an independent risk factor for future cardiovas-
cular events [13]. Processes underlying these structural and mechanical
changes involve growth and migration of vascular smooth muscle cellsAged - Hypertension
Endothelial dysfunction
M:L ratio
Vascular remodelling
Increased stiffness
Vascular inflammation 
Calcification
opment of hypertension. Vascular changes in hypertension mimic those found in arteries
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collagen and elastin in the vascular wall. Physiologically, the ratio of
collagen and elastin remains constant due to their gradual production
and degradation. In aged rodents the absolute elastin content of the
aortawas shownnot to differ to young counterparts. However, increased
collagen content in 30-month-old animals compared to 6-month-old an-
imals meant that the relative elastin content was decreased [14]. Colla-
gen and elastin are regulated by catabolic matrix metalloproteinases
(MMPs). Throughout ageing the balance betweenMMPs and their inhib-
itors (TIMPs) changes. For example, increased MMP-2 expression and
activity in the vessels of old rats and non-human primates is increased
compared to young counterparts [15,16].
3. Vascular calciﬁcation
Vascular calciﬁcation is a tightly controlled process similar to bone
formation, where mineralization of the internal elastic lamina and elas-
tic ﬁbres in the media results in vascular stiffening. Calciﬁcation of the
vascular media is a hallmark of vascular ageing [17]. Upregulation of
transcription factors such as cbfa1 (core-binding factor 1α)/Runx2,
MSX-2 and bone morphogenetic protein 2 (BMP-2), are involved in
normal bone development and vascular calciﬁcation by regulating the
expression of osteogenic proteins, including osteocalcin, osteonectin, al-
kaline phosphatase, collagen-1, and bone sialoprotein [18,19]. Another
mechanism contributing to vascular mineralization is loss of calciﬁca-
tion inhibitors, such as fetuin-A, matrix Gla protein, pyrophosphate,
and osteopontin [19–21]. Molecular processes underlying this remain
to be fully deﬁned but increased expression of BMP2 and the osteoblast
transcription factor Runx2/Cbfa1 [22], and modulation of Ca2+ and
Mg2+ transport through cation channels, such as TRPM7may represent
important mediators in this process [23,24]. A correlation between age
and vascular calciﬁcation has been described from 5% in individuals
younger than 50 years to N12% in individuals older than 80 years [25].
Ageing-associated vascular calciﬁcation has been reported in the aorta
of rodents where the associated mechanisms include dysregulation of
Matrix Gla protein [26]. Further possible mechanisms contributing to
increased calciﬁcation with ageing includes dysregulation of vascular
pyrophosphate [27,28]. Human studies have shown a weak inverse
correlation between age and plasma pyrophosphate [29,30].
4. Ageing associated vascular inﬂammation
With ageing there is a shift towards a proinﬂammatory vascular
phenotype with upregulation of inﬂammatory cytokines, chemokines
and adhesion molecules in the vascular wall [8,9,31–38]. Pro-
inﬂammatory transcription factors and proteins that have been
identiﬁed in the ageing vascular media include MCP-1, TGF-β1, MMP-
2, AP-1 andNF-kB [8,9,39]. Expression and activation of thesemolecules
increases with ageing, processes that are usually associated with in-
creased generation of reactive oxygen species (ROS). In aged arteries,
there is downregulation of the transcription factor, nuclear factor
(erythroid-derived 2)-like 2 (Nrf2), which stimulates expression of
antioxidant enzymes, thereby leading to decreased anti-oxidant poten-
tial and increased ROS bioavailability with consequent oxidative
stress [40]. Oxidative stress is a potent inducer of redox-sensitive pro-
inﬂammatory signalling pathways, further contributing to inﬂamma-
tion and vascular damage with ageing [36–40].
5. Vascular contractility and ageing
Functionally, vascular contraction is altered during ageing and is
determined in large part by changes in vascular smooth muscle cell
cytoskeletal organisation and impaired contractile signalling.Mesenteric
arteries from aged rats demonstrate hypercontractility in response to
phenylephrine compared to young controls [40] an effect which is mir-
rored in the aorta [41]. These ﬁndings are paralleled in studies utilisingthe senescence-accelerated mouse (SAM-P8), which demonstrate in-
creased vascular contractility in response to phenylephrine [42]. Con-
versely, studies performed on carotid vessels from aged guinea pigs
displayed reduced contractile response to both phenylephrine and
endothelin-1 (ET-1) compared to younger controls [43]. Thus it appears
that differential responses during ageing may differ between species.
At the cellular level, with ageing, vascular smooth muscle cells,
which are normally contractile, undergo phenotypic changes to become
stiff and pro-migratory. Subsets of apoptotic, senescent andproliferative
cells as well as hyper-contractile cells may co-exist in the vascular
media. A major trigger for these functional changes is an increase in
intracellular free Ca2+ concentration ([Ca2+]i), which occurs following
activation of phopholipase C (PLC) leading to the generation of
second messengers insitol trisphosphate (IP3) and diacylglycerol
(DAG) [39,44]. Ca2+ binds to calmodulin facilitating an interaction
with myosin light chain kinase (MLCK) leading to its activation. Activat-
ed MLCK triggers phosphorylation of the regulatory light chains of myo-
sin (MLC20) promoting cycling of myosin cross-bridges with actin and
consequent contraction. Dephosphorylation of MLC20 by myosin light
chain phosphatase (MLCP) results in VSMC relaxation. As such, the rela-
tive activities of MLCK and MLCP determine vascular smooth muscle
tone by inﬂuencing the degree of MLC20 phosphorylation. Arteries
fromaged animals display altered responses to various contractile agents
including norepinephrine, serotonin and KCL [44,45]. Mechanisms for
this are incompletely understood, but the percentage of phosphorylated
MLC20 induced by vasoactive agonists is different in young versus aged
rats andmay play a role in altered age-related contractile responses [45].
6. Endothelial function and ageing
The vascular endothelium is a monolayer of cells that lines blood
vessels and plays a key role in arterial function through synthesis and
release of biologically active molecules that can inﬂuence endothelial
function in an autocrine or paracrine fashion. The healthy endothelium
is characterised by a vasodilatory, anti-inﬂammatory and anti-
thrombotic phenotype. Endothelial dysfunction is characterised by
reduced vasodilatory responses to ﬂow or agonists and is pro-
inﬂammatory. Independent of the occurrence of other pathologies,
ageing results in altered endothelium-dependent relaxation of both
the aorta and resistance arteries in rodents [46,47]. These ﬁndings
have been corroborated in human studies that suggest that endothelial
function is gradually compromised with ageing [48,49]. A primary
mechanism responsible for the deterioration of endothelial function
with ageing is thought to be reduced bioavailability of the endothelium
derived relaxing factor, nitric oxide (NO), due to its interactionwith ROS
to form peroxynitrite. Peroxynitrite oxidises BH4, an essential cofactor
for NO synthesis by endothelial nitric oxide synthase (eNOS), to its inac-
tive form resulting in reduced NO production. Furthermore, reduced
BH4 can result in eNOS uncoupling whereby superoxide is produced
in preference to NO. Reductions in BH4 levels have been reported in
aged rodents [50].
7. Vascular signalling in ageing
Molecular mechanisms and cell signalling events underlying the
structural and functional alterations observed during ageing are similar
to those that occur in hypertension (Fig. 2). Many age/longevity-related
molecules and signalling cascades have been described, of which a few
of the novel systems are highlighted below.
7.1. Sirtuins
Sirtuins (SIRTs) are a family of NAD-dependent protein deacetylases
and ribosyl transferases consisting of 7 members which are localised in
the cytoplasm (SIRT1 and SIRT2), nucleus (SIRT1, SIRT2, SIRT 6 and SIRT
7) or mitochondria (SIRT3, SIRT4 and SIRT 5). SIRTs have been
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Fig. 2.Molecular and cellular mechanisms associated with vascular changes in ageing and hypertension. Activation of pro-ﬁbrotic, pro-inﬂammatory, redox-sensitive and growth/apoptotic
signalling pathways lead to changes in vascular structure,mechanics and functionwith resultant arterial remodelling, calciﬁcation, inﬂammation, stiffness and impaired vasoreactivity. These
vascular alterations are common features during ageing and in hypertension. VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesionmolecule-1; MMP, matrix metallo-
proteinases; TIMP, tissue inhibitor of metalloproteinase; RAS, renin angiotensin system; ET-1, endothelin-1; NO, nitric oxide.
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ing, apoptosis, inﬂammation and mitochondrial biogenesis. SIRTs are
able to modulate the ageing process in a number of species [51–53].
This is highlighted by the following: 1) SIRT1 protects against
phosphate-induced arterial calciﬁcation, possibly due to the inhibition
of osteoblastic transdifferentiation [54]; 2) mitochondrial localised
SIRT3 regulates many proteins that are important in the regulation of
mitochondrial function including pyruvate dehydrogenase, SOD2 and
cyclophilin D; 3) SIRT3−/− mice exhibit accelerated cardiovascular
ageing [55] and 4) SIRT3 has vasoprotective effects through interaction
with FOXO3, which enhances mitochondrial antioxidant defence
systems [56].
7.2. PGC-1α
Another emerging candidate implicated in age-related signalling in
the vasculature, is peroxisome proliferator-activated receptor gamma
coactivator-1α (PGC-1α), which plays an important role in regulating
mitochondrial biogenesis and turnover [57]. Because mitochondria re-
quire continuous recycling and regeneration throughout the lifespan
and are subject to continuous damage over time, regulation of mito-
chondrial biogenesis and turnover is critical for maintained energy
production and prevention of oxidative damage, and the promotion of
healthy ageing. Impaired mitochondrial biogenesis is an important in-
ducer of age-related changes in the endothelium and vascular smooth
muscle [58–60]. The aged vasculature displays reduced levels of PGC-
1αwith consequent mitochondrial dysregulation of the electron trans-
port chain and other mitochondrial proteins leading to oxidative stress
and vascular injury [60]. Decreased AMPK activity may contribute toreduced PGC-1α activation and impairedmitochondrial function associ-
ated with ageing [61].
7.3. FoxO transcription factors
The FoxO family of Forkhead transcription factors are involved in
tumour suppression, energy metabolism, and longevity. Mammals ex-
press four FoxO isoforms, FoxO1, FoxO3, FoxO4 and FoxO6. FoxO1,
FoxO3 and FoxO4 are phosphorylated in an Akt-dependent manner
that promotes FoxO export from the nucleus to the cytoplasm, thereby
repressing FoxO transcriptional function. FoxO targets include genes
that have pivotal roles in cell cycle progression (p21, p27) and ROS de-
toxiﬁcation (MnSOD) and thus may be important in regulation of the
ageing phenotype in the vasculature [62,63]. FoxO3 is a direct target
of SIRT3 deacetylation protecting mitochondria against age-related ox-
idative stress and promoting upregulation of genes that are essential
for mitochondrial homeostasis [64]. Several reports have suggested
that FoxO3 may be a determinant of ageing, due to the fact that
single-nucleotide polymorphisms in the FoxO3 gene are associated
with longevity in humans [65,66]. FoxO3 knockout mice however do
not exhibit reduced lifespan [67], and as such, the exact role of FoxO3
in longevity and ageing still remains unclear.
7.4. p66shc
Mitochondrial dysfunction and increased mitochondrial-derived
ROS have been implicated in vascular changes in ageing [68]. An impor-
tant mediator of mitochondrial ROS production and thus regulator of
the intracellular pathways that govern oxidative stress, apoptosis, and
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ylated at serine 36 by PKCβ and VEGF, resulting in recognition by the
prolyl isomerase Pin1, allowing translocation and entrance into mito-
chondria where it interacts with cytochrome C resulting in production
of H2O2. Levels of p66shc in heart, kidney and vascular smooth muscle
increase with ageing [69]. Mice lacking p66shc gene display a 30%
increase in lifespan compared to wild-type controls due to prevention
of oxidative stress and improved endothelial function [70,71].
7.5. Cell cycle regulators, senescence and autophagy
In culture, vascular cells respond to prolonged series of replication
and stresses by eventually entering an irreversible growth arrest or
senescent state [72]. After the Hayﬂick limit, cells enter an irreversible
cell cycle arrest in the G1 phase of the cell cycle and no longer respond
to growth stimuli. This phenomenon is called replicative senescence
and occurs in vascular ageing [73]. Senescent cells have a distinct
phenotype—they are large and ﬂattened, express speciﬁc markers
(β-galactosidase), overexpress cell cycle molecular markers (p16 and
p21), form heterochromatic foci (yH2AX) and accumulate lipofuscin, a
non-degradableﬂuorescent compound [74].Whilst themolecularmech-
anisms underlying cellular senescence have been the focus of numerous
studies, the impact of senescence in vivo has yet to be fully established,
especially since some studies show increased rates of vascular cell prolif-
eration in ageing and longevity [75,76].
Considering the remarkable plasticity of vascular smooth muscle
cells, there is a requirement for tight control of transcriptional,metabol-
ic and ultrastructural processes, events that are coordinated through
autophagy. Autophagy is the basic cellular mechanism that involves
cell degradation of unnecessary or dysfunctional molecules through
lysosomes [77]. In the vasculature, changes in autophagy have been
observed in experimental ageing [78].
7.6. Mitogen-activated protein kinases (MAPK)
Protein kinases are major regulators of signal transduction that
catalyse the phosphorylation of other proteins, thus regulating their ac-
tivity. Primary targets of protein kinases include transcription factors
which modulate intracellular signalling via speciﬁc alteration of down-
stream gene expression/activity [79]. A key group of protein kinases in
the vasculature are the serine/threonine sub-family, which act by pro-
moting phosphorylation of theOHgroup of serine or threonine residues
on target proteins [80]. Mitogen activated protein kinases (MAPKs)
represent a large family of proteins important in signal transduction
within the cardiovascular system, where they are involved in regulation
of a number of biological processes, such as cell migration, survival, ap-
optosis, proliferation, contraction anddifferentiation.MAPK signalling is
promoted bymany stimuli including GPCR activation, receptor tyrosine
kinases, oxidative stress and growth factors, and comprises a number of
sequentially acting kinases which ultimately result in phosphorylation
and activation of terminal effector kinases, thereby transducing speciﬁc
cellular actions [80,81]. SeveralMAPK family subgroups have been iden-
tiﬁed, of which the major mammalian types appear to be ERK1/2, c-Jun
NH2-terminal kinases (JNK1, 2 and 3) and p38MAPK (α, β, δ and γ),
which play key roles during cardiovascular development and vascular
function [82,83]. Several studies have demonstrated an age-dependent
increase in MAPK activation in vascular tissue [84,85].
7.7. Oxidative stress in vascular ageing
Common to many of the molecular and cellular processes described
above that underlie changes in the vasculature with ageing is oxidative
stress [86]. The concept that ROS are linked to ageing was suggested in
1956 by Harman when he proposed the Free Radical Theory of Ageing,
stating that the accumulation of free radicals during ageing causes the
damage of biomolecules by these ROS and the development ofpathological disorders promoting cell senescence and organism ageing
[87,88]. Such processes are evident in vessels associated with ageing
and with hypertension [87,88]. Excessive production of ROS and reac-
tive nitrogen species (RNS) leads to oxidative modiﬁcation of proteins,
DNA and lipids, which accumulate in cells leading to impaired cellular
and vascular function. In addition increased vascular ROS levels, togeth-
er with decreased eNOS-generated NO, compromise the vasodilatory
actions of NO and promote the formation of injurious peroxynitrite,
processes observed in aorta of aged rodents [89]. Oxidative stress is
critically involved in many of the molecular events of vascular ageing,
including: (1) increased pro-inﬂammatory responses in vascular cells,
(2) vascular dysfunction through oxidative modiﬁcation of structural
and functional proteins regulating vascular contraction/relaxation,
ﬁbrosis and calciﬁcation, (3) altered calcium homeostasis in vascular
cells, 4) activation of redox-sensitive pro-inﬂammatory and pro-
ﬁbrotic transcription factors, and (4) activation of molecular mecha-
nisms leading to senescence and autophagy in endothelial and vascular
smoothmuscle cells (Fig. 3). The fact that SODmimetics, such as tempol,
normalise endothelial dysfunction in old rodents supports a role for in-
creased superoxide anion levels in age-related endothelial impairment
[90].
Changes in cellular anti-oxidant systems are also important. The ex-
pression and activity of antioxidant enzymes, including SOD, decline as
tissues age. Decreased anti-oxidant capacity is further promoted by
downregulation of Nrf2, the master transcription factor regulating
anti-oxidant genes [91]. These processes are accompanied by chronic
low-grade inﬂammation mediated by redox-sensitive NFκB, which is
upregulated in aged vessels [92].
Multiple oxidases generate ROS in the vascular wall and endotheli-
um, including NADPH oxidases (Nox), xanthine oxidase, uncoupled
NOS and mitochondrial oxidases. Of these, mitochondria seem to play
a major role in processes related to ageing. Noxs, of which there are 7
isoforms (Nox1-5, Duox1, Duox2), have also been shown to contribute
to oxidative stress in vascular ageing [93–95]. In particular, in aged
spontaneously hypertensive rat aortas, expression of Nox1 and Nox2,
but not of Nox4, was increased. This Nox upregulation was associated
with endothelial dysfunction, which was reversed by VAS2870, a Nox
inhibitor [96]. Noxs appear to bemore important in pathological vascu-
lar remodelling associated with hypertension and cardiovascular
diseases [97–99]. Vascular xanthine oxidase and cytochrome P450
epoxygenases seem to be less important, since expression and activity
of these systems is not altered with ageing in humans [100].
With biological ageing, mitochondria become dysfunctional leading
to reduced energy production and increased ROS formation. Mecha-
nisms related to mitochondrial dysfunction during ageing include
decreased ATP synthesis, increased apoptosis and mutations of mito-
chondrial DNA by oxidation [101]. During ageing, the electron ﬂow in
mitochondria decreases, altering the oxygen consumption and inducing
ROS generation [101]. The pro-oxidative environment increases mito-
chondrial DNAdamage, leading to further dysfunction of the respiratory
chain andmore ROS production. Consequently, the rate of apoptosis in-
creases, releasing an excessive amount of ROS into the cytosol, further
contributing to oxidative stress and vascular cell damage.
7.8. Endoplasmic reticulum stress in vascular ageing
Prolonged perturbation of the endoplasmic reticulum (ER) leads to
ER stress and unfolded protein response (UPR) and contributes to path-
ogenic processes associated with vascular damage and endothelial dys-
function [102]. The ER is an important site where proteins are folded
andpost-translationmodiﬁcations occur. It is also a site for Ca2+ storage
and cholesterol/lipid biosynthesis. Due to the large amount of unfolded
protein in the ER, a control system that avoids protein aggregation and
accumulation of unfolded proteins is necessary. In experimentalmodels
of ageing, the expression and activity of ER chaperones or folding
enzymes decay, whilst oxidative damage, such as carbonylation, is
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as inﬂammation, senescence, ﬁbrosis, calciﬁcation, and hypertrophy in the vasculature. Oxidation of transcription factors that regulate the anti-oxidant capacity in vascular cells, such as
Nrf2, are also affected by oxidation leading to decreased activity. Sources responsible for the increase in ROS generation and oxidativemodiﬁcation of cellularmolecules are themitochon-
dria, NADPH oxidases (Nox) and endoplasmic reticulum (ER) stress.
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and ER stress. This activates signalling mechanisms that are part of the
UPR. Induction of ER stress leads to endothelial cell apoptosis, but not
senescence, implicated in endothelial dysfunction in ageing [103,104].
Inhibition of ER stress has been suggested as a novel therapeutic strate-
gy to ameliorate vascular dysfunction during ageing [105]. However
such approaches still require further investigation.
7.9. Vascular changes in hypertension recapitulate those in ageing
Many of the signalling pathways associated with vascular changes
during ageing are also activated in hypertension leading to endothelial
dysfunction, vascular inﬂammation, remodelling and increased arterial
stiffness. With normal physiological ageing the process is gradual and
regulated but in itself represents a strong and independent risk factor
for hypertension and future cardiovascular events [106]. In susceptible
individuals, due to genetic, environmental or in-utero factors 9fetal pro-
gramming), processes underlying vascular changes are accelerated
leading to ‘early vascular ageing’, which predisposes to cardiovascular
disease. Numerous risk factors amplify the process of arterial ageing, in-
cluding atherosclerosis, smoking, increased sodium intake and hyper-
tension, due, in part, to increased oxidative stress, activation of pro-
inﬂammatory and pro-ﬁbrotic signalling pathways and upregulation
of the renin–angiotensin–aldosterone system. As with ageing, experi-
mental and human hypertension show a reduction in endothelium-
dependent vasodilation, decreased NO bioavailability, NO synthase
uncoupling, increased oxidative stress, telomere shortening and associ-
ated endothelial dysfunction. In arteries fromaged humans, non-humanprimates and rodents, expression of the AT1R is increased and sensitiv-
ity of the mineralocorticoid receptor to aldosterone is enhanced,
phenomena that are also observed in hypertension [107–109]. Ang II
promotes vascular calciﬁcation, inﬂammation, cell proliferation and
ﬁbrosis and mimics age-associated vascular remodelling in young ro-
dents [110–112]. In large arteries thesemolecular and cellular processes
manifest as increased arterial stiffness, which is a major contributor to
elevated central blood pressure leading to isolated systolic hyperten-
sion, common in the elderly. Exactly what triggers these cellular and
vascular events remains unclear, and it is difﬁcult to dissect out the ‘age-
ing effect’ from the ‘blood pressure effect’. This ‘conundrum of arterial
stiffness, elevated blood pressure and ageing’ has recently been
reviewed by AlGhatrif and Lakatta [113], who concluded that vascular
properties depend on the net effect of multiple factors that are interde-
pendent and which change with ageing over a lifetime.
7.10. Effects of pro-hypertensive stimuli on vascular ageing: the renin–
angiotensin–aldosterone system (RAAS)
The RAAS plays an important role in functional, structural and
mechanical changes of the vasculature that occur with ageing and hy-
pertension [114]. This occurs through increased signalling via the AT1
receptor. Expression of various components of the RAS, including
angiotensinogen, chymase, angiotensin converting enzyme (ACE) and
the AT1 receptor is increased in arteries of aged rodents and humans
[8,9]. To further support a role for the RAAS in the ageing process and
duringhypertension are studies showing that ACE inhibitors andAT1 re-
ceptor blockers decrease ageing-associated vascular damage. Mice
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increase in life span [115,116]. Processes associated with these effects
involve upregulation of NOS activity and increased NO production.
An increase in antioxidant defences, such as SOD and glutathione, is an-
other mechanism involved in the anti-ageing effects of the inhibition of
the RAAS system, leading to an increase in NO bioavailability [117].
Moreover, lifelong treatment of young stroke-prone spontaneously
hypertensive rats, with AT1 receptor blockers doubles the lifespan by
improving endothelial function and alleviating complications of hyper-
tension [118]. To further support a role for Ang II/AT1 receptor in oxida-
tive stress, vascular injury and ageing, studies in mice with targeted
disruption of the Agtr1a gene, which encodes the AT1A receptor, result-
ed in prolonged life span [119]. Agtr1a−/−mice developed less cardiac
and vascular injury and oxidative damage was reduced compared with
wild-type counterparts. The longevity phenotype was associated with
an increased number of mitochondria and upregulation of pro-
survival genes.
Clinical and experimental studies demonstrate that many pro-
hypertensive systems inﬂuence processes of vascular ageing, including
aldosterone, ET-1 and growth factors [120–124]. Arteries from aged
rodents demonstrate upregulation of these systems, leading to stimula-
tion of signalling pathways, oxidative stress, and activation of pro-
inﬂammatory transcription factors,which promote a shift of endothelial
and vascular smooth muscle cells to an ageing phenotype. On the other
hand, infusion of Ang II, aldosterone or ET-1in young animals, recapitu-
lates arterial changes observed in aged animals.7.11. Effects of novel anti-hypertensive factors on vascular ageing
NO is a potent vasodilator produced by endothelial cells that medi-
ates vascular relaxation and thus plays a critical role in the regulation
of blood pressure. Abnormalities in endothelial production of NO
occur in hypertension and are due, in large part, to decreased eNOS ac-
tivity [125]. NO donors such as glyceryl trinitrate (GTN) have been
shown to possess anti-hypertensive properties [126] and evidence is
emerging that NO and NO donors could confer beneﬁcial effects on
the phenotypic alterations that occur in the vasculature with ageing.
For example, NO prevents differentiation of VSMCs into osteoblastic
cells by inhibiting TGF-β [127]. The NO donor S-nitroso-penicillamine
signiﬁcantly reduces endothelial cell senescence and age-dependent in-
hibition of telomerase activity [128,129].
The gaseousmessenger hydrogen sulphide (H2S) produced by cysta-
thionine g-lyase (CSE) or cystathionine b-synthase (CBS) has recently
emerged as a novel antihypertensive factor based on the observations
that exogenous H2S is vasoprotective in pulmonary hypertension
[130] and that it reduces systemic blood pressure by improving
endothelial function [131]. CSE-deﬁcient mice, have increased blood
pressure and impaired endothelial function [132]. Mouse embryonic ﬁ-
broblasts from CSE knockout mice display accelerated cellular senes-
cence and increased expression of p53 and p21, processes which were
prevented by NaHS treatment. NaHS also enhanced Nrf2 nuclear trans-
location, and stimulated mRNA expression of Nrf2-targeted down-
stream anti-oxidant genes in this system, highlighting an important
interplay between cellular ageing, senescence and oxidative stress
[133]. Attenuation of endothelial cell senescence by H2S occurs through
modulation of SIRT1 activity [134].
Plasma levels of H2S in humans decline with age [135] and several
studies have shown that H2S protects against free radical-induced
damage and exerts beneﬁcial effects on age-associated diseases [136].
Several lines of evidence indicate that these beneﬁcial effects may
extend to vascular ageing, characterised by positive effects on many of
the phenotypic vascular alterations that occur with advancing age. For
example, the production of H2S is decreased in a rodentmodel of vascu-
lar calciﬁcation with the addition of H2S ameliorating this phenotype
[137]. Further, in vascular smoothmuscle cells, H2S was found to inhibitcalcium deposition in the extracellularmatrix and suppress induction of
osteoblastic transformation genes [138].
In endothelial cells stimulated with TNF-α, NaHS (H2S donor)
suppressed pro-inﬂammatory responses by reducing the TNF-induced
increase in expression of intercellular adhesion molecule-1 (ICAM-1),
vascular cell adhesion molecule-1 (VCAM-1), P-selectin and E-selectin.
Furthermore, TNF-α-induced NF-κB was decreased in the presence of
NaHS [139]. H2S donors (NaHS and Na2S) can inhibit leukocyte adher-
ence inmesenteric venuleswhilst inhibition of endogenousH2S synthe-
sis promotes leukocyte adhesion and vascular inﬂammation [140].
7.12. Vascular damage in hypertension may be independent of ageing
Although there are many signalling pathways and functional and
structural characteristics that are common in vessels during ageing
and hypertension, these processes are dynamic and change throughout
life and as such may not necessarily be superimposable. For example,
with advancing age arterial stiffness and blood pressure start to diverge
rather than parallel [141]. Also, circulating markers of inﬂammation
including sVCAM-1, IL-6 andMCP-1 increase with age but do not neces-
sarily correlate with elevations in blood pressure [142]. Furthermore,
with ageing, aortic calciﬁcation is independently predictive of subse-
quent vascular morbidity and mortality beyond established risk factors
with no evident correlation between calciﬁcation and systolic BP [143].
There is also some evidence to show that structural alterations in the
vascular wall occur before the development of hypertension. For
example rates of pulse wave velocity (PWV) increase are accelerated
with both advancing age and elevated blood pressure. However, the
effect of blood pressure on PWV increase occurs primarily during the
prehypertensive phase and suggests that these vascular alterations
precede the phase of established hypertension [8,144].
7.13. Lessons learned from children with hypertension
Vascular changes that occur with ageing may be independent of
biological ageing in hypertension. This is highlighted in studies that
have examined vascular function and arterial structure in children
with hypertension. Endothelial dysfunction, arterial stiffening and
structural alterations of the arterial wall may precede evidence of high
blood pressure, as quantiﬁed by systolic and diastolic blood pressure,
and may be independent of the ageing process [145]. This is evidenced
by the ﬁndings that vascular injury is already present in children with
mild hypertension, processes that are exaggerated as hypertension be-
comes more severe [146,147]. Functional alterations, including reduced
endothelium-dependent vasorelaxation and decreased elasticity, seem
to precede vascular structural changes. In obese pre-pubertal children,
impaired brachial endothelial and vascular smooth muscle function is
presentwithout concomitant increase in carotid intima-to-media thick-
ness. Functionally these changes lead to decreased vascular distensibil-
ity and increased rigidity or stiffness. Arterial stiffness, as assessed by
measurement of PWV, is increased in children with type 1 diabetes
and in children with hypertension. Increased arterial stiffness in
childhood hypertension is an important risk factor for severe hyperten-
sion and cardiovascular complications later in life. Results from the
Amsterdam Growth and Health Longitudinal Study indicate that indi-
viduals with stiffer carotid arteries at 36 years of agewere characterised
during adolescence by increased blood pressure and increased PWV
[148]. Factors that have been implicated in vascular dysfunction in
childhood hypertension include activation of the sympathetic nervous
system, adipokines, upregulation of the RAAS and increased oxidative
stress, processes that also underlie physiological vascular ageing and
EVA in adult hypertension [149–152].
Taken together, emerging experimental and clinical evidence
indicates that although the molecular and cellular processes that
characterise the vascular phenotype in hypertension resemble those
that occur with normal healthy ageing, age per se may not be a critical
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vascular injury that occurs with blood pressure elevation. In the
presence of other co-morbidities, such as diabetes, dyslipidemia,
smoking and obesity, these processes may be further exaggerated.
8. Summary and conclusions
Ageing is associated with a progressive deterioration in endothelial
function, vascular remodelling, inﬂammation and increased arterial
stiffness. Processes underlying these processes include activation of
pro-inﬂammatory transcription factors, oxidative stress, cell senescence
and apoptosis, aberrant signalling cascades and a shift from a vasocon-
strictor to a proliferative vascular cell phenotype. Many of these
phenomena are also relevant in the pathophysiology of hypertension,
which is characterised by a vascular phenotype of impaired
endothelium-dependent vasorelaxation, arterial remodelling, increased
stiffness and vascular inﬂammation. Through such vascular changes,
ageing and hypertension are closely interlinked: ageing promotes
hypertension and pro-hypertensive factors promote vascular ageing.
Whilst many of the molecular processes and signalling pathways
contributing to vascular dysfunction are common in ageing and in hy-
pertension, biological age per se, may not be a fundamental factor,
since vascular damage is already present in children and young adults
with hypertension. A better understanding of the vascular biology of
ageing will facilitate development of strategies to promote healthy
vessels and suppress age-associated changes, especially in pathological
conditions. Such approaches could prevent or ameliorate vascular
damage in hypertension and hence reduce cardiovascular diseases,
commonly linked to ageing.
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